Abnormalities in the pattern of platelet amyloid precursor protein forms in patients with mild cognitive impairment and Alzheimer disease.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Archives of Neurology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1001/ARCHNEUR.59.1.71PMID 11790233
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Classification criteria for mild cognitive impairment

  2001cited by this paper
• New biochemical markers in Alzheimer disease.

  2001cited by this paper
• Of MCI and dementia: Improving diagnosis and treatment

  2001cited by this paper
• Mild cognitive impairment represents early-stage Alzheimer disease.

  2001cited by this paper
• Platelet amyloid precursor protein forms in AD: a peripheral diagnostic tool and a pharmacological target.

  2001influential reference
• Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss.

  2001cited by this paper
• Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

  2001cited by this paper
• Evidence That Age-Associated Memory Impairment Is Not a Normal Variant of Aging

  2001cited by this paper
• Amyloid precursor protein in platelets of patients with Alzheimer disease: effect of acetylcholinesterase inhibitor treatment.

  2001cited by this paper
• 'Prodromal Alzheimer's disease': a more useful concept than mild cognitive impairment?

  2000cited by this paper
• Predicting conversion to Alzheimer disease using standardized clinical information.

  2000cited by this paper
• Platelet APP isoform ratios correlate with declining cognition in AD

  2000influential reference
• Platelets as a peripheral district where to study pathogenetic mechanisms of alzheimer disease: the case of amyloid precursor protein.

  2000cited by this paper
• Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease.

  2000cited by this paper
• Mild cognitive impairment: conceptual basis and current nosological status

  2000cited by this paper
• Aging, mild cognitive impairment, and Alzheimer's disease.

  2000cited by this paper
• Plasma and cerebrospinal fluid Levels of amyloid β proteins 1-40 and 1-42 in Alzheimer disease

  2000cited by this paper
• Improved discrimination of AD patients using β-amyloid(1-42) and tau levels in CSF

  1999cited by this paper
• Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease

  1999cited by this paper
• Mild Cognitive Impairment Clinical Characterization and Outcome

  1999cited by this paper
• Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment.

  1999influential reference
• Cognitive process in preclinical phase of dementia.

  1998cited by this paper
• Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets.

  1998cited by this paper
• Alzheimer disease-related abnormalities of amyloid beta precursor protein isoforms in the platelet: the brain's delegate in the periphery?

  1998cited by this paper
• Platelet activation in Alzheimer disease.

  1998cited by this paper
• Differential level of platelet amyloid beta precursor protein isoforms: an early marker for Alzheimer disease.

  1998cited by this paper
• Progression to dementia in patients with isolated memory loss.

  1997cited by this paper
• Altered amyloid protein processing in platelets of patients with Alzheimer disease.

  1997cited by this paper
• Activated Alzheimer disease platelets retain more beta amyloid precursor protein.

  1997cited by this paper
• Diagnosis and treatment of Alzheimer disease and related disorders. Consensus statement of the American Association for Geriatric Psychiatry, the Alzheimer's Association, and the American Geriatrics Society.

  1997cited by this paper
• Cerebrospinal protein tau is elevated in early Alzheimer's disease.

  1996cited by this paper
• Abnormal pattern of platelet APP isoforms in Alzheimer disease and Down syndrome.

  1996cited by this paper
• Prediction of probable Alzheimer's disease in memory-impaired patients

  1996cited by this paper
• Changes in platelet phospholipase C protein level and activity in Alzheimer's disease.

  1995cited by this paper
• Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease.

  1995cited by this paper
• Reduction of β‐amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease

  1995cited by this paper
• Platelet protein kinase C levels in Alzheimer's disease.

  1994cited by this paper
• The Neuropsychiatric Inventory

  1994cited by this paper
• Lacunes

  1993cited by this paper
• Clinically Diagnosed Alzheimer Disease: Neuropathologic Findings in 650 Cases

  1992cited by this paper
• Mild cognitive impairment in the elderly

  1991cited by this paper
• Psychometric construction of the Rey-Osterrieth Complex Figure: methodological considerations and interrater reliability.

  1990cited by this paper
• The amyloid precursor protein of Alzheimer's disease is released by human platelets.

  1990cited by this paper
• Screening for Alzheimer's Disease by Clock Drawing

  1989cited by this paper
• Reliability of the Washington University Clinical Dementia Rating.

  1988cited by this paper
• Beta-amyloid precursor protein of Alzheimer disease occurs as 110- to 135-kilodalton membrane-associated proteins in neural and nonneural tissues.

  1988cited by this paper
• Geriatric Depression Scale (GDS): Recent evidence and development of a shorter version.

  1986cited by this paper
• Clinical diagnosis of Alzheimer's disease

  1984cited by this paper
• A new rating scale for Alzheimer's disease.

  1984cited by this paper
• The Hamilton Anxiety Scale. Evaluation of homogeneity and inter-observer reliability in patients with depressive disorders.

  1983cited by this paper
• Repeatability and validity of a modified activities of daily living (ADL) index in studies of chronic disability.

  1979cited by this paper
• “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician

  1975cited by this paper
• The Set Test as an Aid to the Detection of Dementia in Old People

  1973cited by this paper
• Assessment of older people: self-maintaining and instrumental activities of daily living.

  1969cited by this paper
• Raven's progressive matrices: construct validity.

  1966cited by this paper
• Validity of the Trail Making Test as an Indicator of Organic Brain Damage

  1958cited by this paper
• Test and manual of directions; the revised examination for the measurement of efficiency of mental functioning.

  1940cited by this paper
• CME Practice parameter:

  year unknowncited by this paper

• ROS-dependent localization of glycolytic enzymes to mitochondria

  2025cites this paper
• Early Diagnosis of Alzheimer’s Disease with Blood Test; Tempting but Challenging

  2023cites this paper
• Biomarkers in the diagnosis of neurodegenerative diseases

  2022cites this paper
• Altered Microcirculation in Alzheimer’s Disease Assessed by Machine Learning Applied to Functional Thermal Imaging Data

  2022cites this paper
• Can platelet activation result in increased plasma Aβ levels and contribute to the pathogenesis of Alzheimer's disease?

  2021cites this paper
• Platelet APP Processing: Is It a Tool to Explore the Pathophysiology of Alzheimer’s Disease? A Systematic Review

  2021cites this paper
• The Inflammasome Adaptor Protein ASC in Mild Cognitive Impairment and Alzheimer’s Disease

  2020cites this paper
• Effect of a Cognitive Training Program on the Platelet APP Ratio in Patients with Alzheimer’s Disease

  2020cites this paper
• Biomarkers in Alzheimer’s disease: Evaluation of platelets, hemoglobin and vitamin B12

  2020cites this paper
• Platelet Amyloid-β Protein Precursor (AβPP) Ratio and Phosphorylated Tau as Promising Indicators for Early Alzheimer's Disease.

  2019cites this paper
• Amyloid peptides and the vascular system : the link between cerebrovascular angiopathy and Alzheimer's disease

  2019cites this paper
• Biomarkers for Alzheimer´s disease.

  2019cites this paper
• Platelets: Peripheral Biomarkers of Dementia?

  2018cites this paper
• A potential impact of Helicobacter pylori‐related galectin‐3 in neurodegeneration

  2018cites this paper
• Molecular Markers of Early Diagnosis of Alzheimer Disease: Prospects for Research in Peripheral Tissues

  2018cites this paper
• Multivariate analyses of peripheral blood leukocyte transcripts distinguish Alzheimer's, Parkinson's, control, and those at risk for developing Alzheimer's.

  2017cites this paper
• The Distinction of Amyloid-β Protein Precursor (AβPP) Ratio in Platelet Between Alzheimer’s Disease Patients and Controls: A Systematic Review and Meta-Analysis

  2017influential citation
• Platelets: Their Potential Contribution to the Generation of Beta-amyloid Plaques in Alzheimer's Disease.

  2017cites this paper
• Current status of biomarker research in neurology

  2016cites this paper
• Potential fluid biomarkers for pathological brain changes in Alzheimer's disease: Implication for the screening of cognitive frailty

  2016cites this paper
• Amyloid precursor protein in peripheral granulocytes as a potential biomarker for Alzheimer’s disease

  2016cites this paper
• Platelets in Alzheimer’s Disease

  2015cites this paper
• Child and Adolescent Psychiatry.

  2015cites this paper
• Occupational exposure to aluminum and its amyloidogenic link with cognitive functions.

  2014cites this paper
• Biomarkers of Alzheimer’s Disease Risk in Peripheral Tissues; Focus on Buccal Cells

  2014cites this paper
• Alzheimer and platelets: low-density platelet populations reveal increased serotonin content in Alzheimer type dementia.

  2014cites this paper
• Blood Test for Early Diagnosis of Alzheimer’s Disease

  2013cites this paper
• Mild cognitive impairment. Part 2: Biological markers for diagnosis and prediction of dementia in Alzheimer's disease.

  2013cites this paper
• Correlation Between Mini-Mental State Examination and Platelet ADAM10 Expression in Alzheimer's Disease

  2013cites this paper
• The development of effective biomarkers for Alzheimer's disease: a review

  2013cites this paper
• The platelet amyloid precursor protein ratio as a diagnostic marker for Alzheimer's disease in Thai patients.

  2013cites this paper
• Abnormal Platelet Amyloid-β Protein Precursor (AβPP) Metabolism in Alzheimer's Disease: Identification and Characterization of a New AβPP Isoform as Potential Biomarker

  2013cites this paper
• Alzheimer's Disease Modeling: Ups, Downs, and Perspectives for Human Induced Pluripotent Stem Cells

  2013cites this paper
• Laser Raman detection for oral cancer based on a Gaussian process classification method

  2013cites this paper
• Laser Raman detection of platelets for early and differential diagnosis of Alzheimer’s disease based on an adaptive Gaussian process classification algorithm

  2013cites this paper
• Detection of Alzheimer's disease by Raman spectra of rat's platelet with a simple feature selection

  2013cites this paper
• QT dispersion in mild cognitive impairment: a possible tool for predicting the risk of progression to dementia?

  2013cites this paper
• Processing of the Platelet Amyloid Precursor Protein in the Mild Cognitive Impairment (MCI)

  2013cites this paper
• Alzheimer disease and platelets: how’s that relevant

  2012cites this paper
• In Search of Therapeutic Solutions for Alzheimer’s Disease

  2012cites this paper
• Platelets and Alzheimer's disease: Potential of APP as a biomarker.

  2012cites this paper
• Platelet Tau Pattern Correlates with Cognitive Status in Alzheimer's Disease

  2012cites this paper
• Development of biomarkers to chart all Alzheimer's disease stages: The royal road to cutting the therapeutic Gordian Knot

  2012cites this paper
• 6 In Search of Therapeutic Solutions for Alzheimer ’ s Disease

  2012cites this paper
• Platelet biomarkers in Alzheimer's disease.

  2012cites this paper
• Biomarkers for Alzheimer Disease in Cerebrospinal Fluid, Urine, and Blood

  2012cites this paper
• When Things Go Wrong - Diseases and Disorders of the Human Brain

  2012cites this paper
• Blood-Based Protein Biomarkers for Diagnosis and Classification of Neurodegenerative Diseases

  2011influential citation
• Laser Raman detection of platelet as a non-invasive approach for early and differential diagnosis of Alzheimer's disease

  2011cites this paper
• Human Platelets Tau: A Potential Peripheral Marker for Alzheimer's Disease

  2011cites this paper
• Biomarkers in Alzheimer's disease drug development

  2011cites this paper
• Epigenetics in Alzheimer's disease: a focus on DNA modifications.

  2011cites this paper
• Selective Interaction of Lansoprazole and Astemizole with Tau Polymers: Potential New Clinical Use in Diagnosis of Alzheimer's Disease

  2010cites this paper
• Blood cell markers in Alzheimer Disease: Amyloid Precursor Protein form ratio in platelets.

  2010cites this paper
• Biomarkers of Alzheimer’s disease in body fluids

  2010cites this paper
• Biomarkers and Surrogate Markers in Drug Development

  2010cites this paper
• Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease

  2009cites this paper
• Biological Marker Candidates of Alzheimer's Disease in Blood, Plasma, and Serum

  2009influential citation
• [Biomarkers for early diagnosis of Alzheimer's disease: current update and future directions].

  2009cites this paper
• New perspectives for the diagnosis of Alzheimer's disease.

  2009cites this paper
• Featured Articles Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease

  2009cites this paper
• Extração das isoformas da proteína precursora do amilóide em plasma rico em plaquetas para testes proteômicos como biomarcador da doença de Alzheimer

  2008cites this paper
• Platelet β-secretase activity is increased in Alzheimer's disease

  2008cites this paper
• Platelet beta-secretase activity is increased in Alzheimer's disease.

  2008cites this paper
• Biomarkers of mild cognitive impairment and Alzheimer's disease.

  2008cites this paper
• Ovariectomy increases neuronal amyloid-beta binding alcohol dehydrogenase level in the mouse hippocampus.

  2008cites this paper
• Oxidative stress: A bridge between Down's syndrome and Alzheimer's disease

  2007cites this paper
• Association between Helicobacter pylori infection and mild cognitive impairment

  2007cites this paper
• Biomarkers of neurodegeneration for diagnosis and monitoring therapeutics

  2007cites this paper
• The role of biologic markers in the diagnosis of Alzheimer's disease

  2007cites this paper
• Correlation between Platelet Amyloid Precursor Protein Isoform Ratio and Cognition in Alzheimer's Disease

  2007cites this paper
• Chapter 3 Mild Cognitive Impairment

  2007cites this paper
• Elevated Platelet β-Secretase Activity in Mild Cognitive Impairment

  2007cites this paper
• Coated-platelets correlate with disease progression in Alzheimer disease

  2007cites this paper
• Elevated platelet beta-secretase activity in mild cognitive impairment.

  2007cites this paper
• Abnormal APP processing in platelets of patients with Alzheimer’s disease: correlations with membrane fluidity and cognitive decline

  2007cites this paper
• Clinical evaluation as a biomarker for Alzheimer's disease

  2006cites this paper
• Combined 99mTc-ECD SPECT and neuropsychological studies in MCI for the assessment of conversion to AD.

  2006cites this paper
• Circulating biomarkers of cognitive decline and dementia.

  2006cites this paper
• Coated-platelets retain amyloid precursor protein on their surface

  2006cites this paper
• Toward a reliable distinction between patients with mild cognitive impairment and Alzheimer-type dementia versus major depression.

  2006cites this paper
• Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment.

  2006cites this paper
• Predicting Alzheimer dementia in mild cognitive impairment patients. Are biomarkers useful?

  2006cites this paper
• Cholinesterase Inhibitor Affects the Amyloid Precursor Protein Isoforms in Patients with Alzheimer’s Disease

  2005cites this paper
• Expression and activity of β-site amyloid precursor protein cleaving enzyme in Alzheimer's disease

  2005cites this paper
• Expression and activity of beta-site amyloid precursor protein cleaving enzyme in Alzheimer's disease.

  2005cites this paper
• Advances on biological markers in early diagnosis of Alzheimer disease.

  2005cites this paper
• Predicting Cognitive Decline in Alzheimer Disease: Role of Platelet Amyloid Precursor Protein

  2004cites this paper
• The Predementia Diagnosis of Alzheimer Disease

  2004cites this paper
• Hormonal and non-hormonal factors associated with cognition in post-menopausal women

  2004cites this paper
• Biomarkers of Alzheimer disease in plasma

  2004cites this paper
• Glutamate transporters in platelets: EAAT1 decrease in aging and in Alzheimer's disease.

  2004cites this paper
• Biological Markers in Alzheimer’s Disease

  2004cites this paper
• Platelets provide human tissue to unravel pathogenic mechanisms of Alzheimer disease.

  2004cites this paper
• Biological markers in Alzheimer disease.

  2003cites this paper
• Update on mild cognitive impairment

  2003cites this paper
• Dementia Update 2003

  2003cites this paper
• Noncholinergic treatment options for Alzheimer's disease.

  2003cites this paper
• Platelet amyloid precursor protein abnormalities in mild cognitive impairment predict conversion to dementia of Alzheimer type: a 2-year follow-up study.

  2003influential citation
• Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease.

  2003cites this paper